This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

Americas

  1. This document, current as of May 25, 2022, provides data and information from PATH's modeling focused on the global supply and demand of autodisable (AD) syringes, which are used for COVID-19 and routine immunizations in more than 100 countries. The cmTent forecast indicates that, despite an estimated gap of 360 million AD syringes in Q 1 2022, production capacity is adequate to meet syringe demand in Q2 2022 through Q3 2023, due to the significant capacity expansions undertaken by manufacturers and slower COVID-19 vaccination uptake than targeted timelines in many countries. The AD syringe gap analysis combines maximum syringe supply capacity collected from manufacturers in Q2 2022 with estimated syringe demand from all countries known to use AD syringes globally, including demand for both COVID- 19 and non-COVID-19 immunizations. Three potential scenarios for AD syringe demand are forecasted to reflect the uncertainty in future demand; the forecast indicates adequate supply in all three scenarios.
    Published: June 2022
    Type: Resource Page
  2. Published: June 2022
    Type: Press Release
  3. PATH malaria experts weigh in on what it will take to accelerate elimination—and what excites them about their work.
    Published: April 2022
    Type: Article
  4. A research study of close contacts of individuals with COVID-19 in Brazil finds that POC rapid antigen tests for SARS-CoV-2 are highly versatile and useful tools for combatting the COVID-19 pandemic. The study demonstrates the near immediate time-to-result of POC rapid antigen tests significantly offsets reduced sensitivity by enabling early identification of positive cases and decreasing onward viral transmission. In settings where RT-PCR is unavailable due to financial or infrastructure limitations, or where time-to-results is >4 days, close to 90% of individuals with Ct<34 could benefit from an earlier result via a POC test. Even in settings where PCR results are available within 24 hours, cumulative sensitivity of a POC test is >70%.
    Published: February 2022
    Type: Resource Page
  5. The Safeprim study evaluated the operational aspects of the SD Biosensor STANDARD™ G6PD screening test performed in real-life settings of two municipalities in the Brazilian Amazon. In order to provide suitable training for health care professionals with different backgrounds at the primary level of care, job aids were created based on materials available within the G6PD Operational Research Community of Practice hosted by PATH. This way, the essential information on test procedure, treatment choice, and pharmacovigilance of hemolysis could be used in the field after a 4-hour training session.A wall poster (29.7x42 cm), folder (21x29.7 cm), and slide set were used during the trainings, while patient cards (8x20 cm malaria card) containing G6PD and malaria data were provided after screening: a green-colored card for normal G6PD status and red-colored card for G6PD deficient. Such cards could be referenced in future malaria episodes.
    Published: December 2021
    Type: Resource Page
  6. If we can't name the problem, we can't defeat it. Enter PATH's initiative to defeat diarrheal disease.
    Published: November 2021
    Type: Article
  7. Global convening of syringe manufacturers and multilateral organizations held to help bolster supply.
    Published: November 2021
    Type: Press Release
  8. Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included a feasibility and acceptability study with national stakeholders and healthcare providers in Ghana, Kenya, Malawi, Peru, Senegal, and Sri Lanka to assess their preferences for different hypothetical rotavirus vaccine options. These briefs provide an overview of the results in each of the study countries.
    Published: October 2021
    Type: Resource Page
  9. Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included: targeted analyses on the ideal age group for iNGRVs and potential future combination vaccine options, impact and cost effectiveness analyses, a feasibility and acceptability study with national stakeholders and healthcare providers in six countries, and a demand forecast. This brief provides a comprehensive summary of the results.
    Published: October 2021
    Type: Resource Page
  10. Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included an impact and cost-effectiveness analysis examining multiple rotavirus vaccine options and strategies. This fact sheet provides an overview of the results.
    Published: October 2021
    Type: Resource Page
Load more